Dr. DeAngelo on Rates of CRS with Obe-cel in ALL
In Partnership With:
Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.
Daniel J. DeAngelo, MD, PhD, associate professor of Medicine, Harvard Medical School, physician, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses rates of cytokine release syndrome (CRS) with obecabtagene autoleucel (obe-cel; formerly AUTO1) in acute lymphoblastic leukemia (ALL).
Obe-cel was previously evaluated in the phase 1 ALLCAR19 trial (NCT02935257) in patients with select B-cell malignancies. The agent will be further explored in patients with ALL in the phase 1/2 FELIX trial (NCT04404660).
Compared with known rates of CRS with other CAR T-cell therapies, patients who received obe-cel had lower instances of severe CRS, DeAngelo explains. Instances of grade 1 or 2 CRS were reported, though there were limited cases of grade 3 or 4, with no cases of grade 5, DeAngelo adds.
Other neurotoxic adverse effects (AEs) were also limited, DeAngelo says. The lower affinity CD-19 binder of obe-cel resulted in less severe T-cell activation, leading to lower rates of severe CRS and neurotoxicity, DeAngelo concludes.
